Established in 1982, we at Randox are dedicated to improving healthcare worldwide with the use of innovative diagnostic technologies. We are passionate about saving lives through the use and development of contemporary and pioneering products. As an international company, headquartered in Northern Ireland, Randox is a major exporter. With having offices and distribution in over 145 countries, manufacturing, and R&D capabilities in 4 jurisdictions across 3 continents.

We are a world leader in the in-vitro diagnostics industry with over 40 years’ experience. Our products offer clinicians and physicians with the most comprehensive insight into patient diagnosis allowing more effective disease management and treatment. Our innovations are not a result of accepting the standard but rooted in our dedication to science and our goal to improving health worldwide. From our diagnostic reagents to quality controls, forensic toxicology to food diagnostics, workplace drug testing to sexual and general health, Randox cultivates lasting relationships with you to improve patient outcomes quickly, accurately, and efficiently.

Our expertise and product portfolio have assisted laboratories across the world in improving diagnostics for clinical healthcare and saving lives. Through a heavily committed research and development programme we continue to offer revolutionary products and solutions specifically designed to provide more efficient, higher quality, and reliable results in the widest variety of laboratory settings. We are advancing the cutting-edge science and technologies that hold the key to ground-breaking improvements in health and practice across the globe.

Improving patient care is our passion. We continually look to develop future innovations believing it is critical to deliver world class heath care solutions right now. Randox is leading the charge in moving from a one-size-fits-all approach towards decisions, practices, and products tailored to the needs of the individual. Our commitment to transforming the lives of patients is matched by our determination to develop new and exciting breakthroughs in science, technology, and engineering.

For more information, visit www.randox.com or email market@randox.com

Menarini Silicon Biosystems Company

Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinicians, clinical researchers, and pharma companies with access to unparalleled resolution in the study of cells and their molecular characterization.

CELLSEARCH® is the first and only clinically validated blood test cleared by the FDA for detecting and enumerating Circulating Tumor Cells (CTCs) to aid in managing patients with metastatic breast, prostate, and colorectal cancers when used in conjunction with other clinical methods (for full intended use see documents.cellsearchctc.com).

DEPArray™ PLUS (for Research Use Only) is an image-based digital cell-sorting and isolation platform that enables clinical researchers to study rare cells with single-cell precision.

The integration of CELLSEARCH® and DEPArray™ technologies provides the most comprehensive cell-based liquid biopsy workflow for the enumeration, sorting, and molecular characterization of rare circulating tumor cells with single-cell precision.

The company Global Biopharma Lab Services offers unique, specialized tools to expedite drug discovery and development programs from preclinical through Phase IV trials.  Two Lab locations, in the United States and Europe, support multicenter, global clinical trials and accept samples from around the world.

Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.

Transgene is a biotechnology company focused on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer (https://www.transgene.fr/en).

The company currently has several products in clinical development (Phase I and II trials): TG4050, an individualized therapeutic vaccine from the myvac® platform, TG4001, a therapeutic vaccine against HPV-positive cancers, and two oncolytic viruses, TG6002, which enables a chemotherapy to be produced directly in the tumor, and BT-001, the first candidate from the Invir.IO™ platform, armed with an anti-CTLA-4 antibody.

Its two next-generation platforms are based on Transgene’s expertise in viral vector engineering, and precision medicine :

• the myvac® approach allows the generation of individualized vaccine-based immunotherapy that encodes patient-specific mutations (neoantigens) predicted by artificial intelligence,
• the Invir.IO™ platform aims at designing multifunctional oncolytic viruses, built on highly tumor-selective pox vectors, and optimized recombinant payloads.

Transgene also relies on strategy collaborations with recognized industry partners, such as AstraZeneca and Merck KGaA/Pfizer, NEC, and BioInvent.

The Company is based in Strasbourg, France, and has additional operations in Lyon. Transgene is listed on the regulated stock market in Paris (Euronext compartment B), with Institut Merieux as a major shareholder.

On December 12, 1968 the Austrian Society of Clinical Chemistry was founded. The first president was Theodor Leipert (1902 – 1992). In order to identify the work of the Society on a local basis, local branches were opened in Graz, Innsbruck, Linz, Salzburg and Vienna on the initiative of Hans Grunicke (Innsbruck). It is the responsibility of the local branches to organize seminars and meetings to enable local members to be actively involved in the
Society. Thanks to Hans Grunicke and Bernd Puschendorf the local branch in Innsbruck developed in the most active one. On the occasion of the 7th IFCC Congress in Geneva in 1969 the OEGKC became a member of the IFCC.
In 1969 the Society introduced the methods of statistical quality control in Austria in cooperation with the Institute of Medical Chemistry at the University of Vienna. In 1980 the organisation of the national surveys was taken over by OEQUASTA (Austrian Society for Quality Assurance and Standardization of Medical Laboratory Investigation). Due to the large number of laboratories run by general practitioners in Austria, the number of participants in
clinical chemistry surveys increased to more than 2000.
International contacts were intensified by holding several joint meetings with other European Societies. In 1981, the 11th IFCC Congress took place in Vienna. The congress was organized by Erich Kaiser, Franz Gabl, Mathias M. Mueller and Peter Michael Bayer. It was generally acknowledged that this congress was a big success and contributed to furthering the international reputation of the Society. The 11th IFCC Congress was followed by numerous national and international congresses and conferences (for instant clinical enzymology, purines and pyrimdines, etc.), which have substantially increased the exchange of information on an international basis.
The Austrian Society of Laboratory Medicine (OEGLM) was founded in 1973. Its primary goal was to support and promote private professionalism of Laboratory Medicine. The OEGLM was a member in the Medical Association of Austria and became a member of WASP. The OEGLM developed postpromotional educational training programmes. Most of them were joined by OEGKC. For several years OEGLM and OEGKC were organizing joint national meetings in Austria.
Thus it was a logical consequence to unify both societies in order to create a stronger national society open for laboratory professionals irrespective of their academic background.
Finally on January 1, 2005 both societies joined their forces and formed the Austrian Society of Laboratory Medicine and Clinical Chemistry (OEGLMKC) integrating national and international responsibilities of the two forerunner societies. The OEGLMKC is now the full member society of IFCC and the WASPaLM (World Association of Societies of Pathology and Laboratory Medicine). The society is a voluntary nonprofit scientific and professional society with the main objective to stimulate and support laboratory diagnostics as an important field in medicine in Austria and globally. In addition to local initiatives its activities include scientific corporations with societies of neighbouring countries resulting in a joint congress with the German Society of Clinical Chemistry and Laboratory Medicine (DGKL) in Vienna 2007 and participation in the Swissmedlab 2008 in Montreux. In 2009 Innsbruck will be hosting the European Congress of Clinical Chemistry and Laboratory Medicine.